🇺🇸 FDA
Patent

US 9321763

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61K31/5377

Quick answer

US patent 9321763 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
64
CPC classes
A61K, A61K31/506, A61K31/5377, A61K31/538, A61K31/5383